Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus

Divya Koura, James Mirocha, Kaitlyn C Dykes, Ayad Hamdan, Aaron Goodman, Tiffany N Tanaka, Carolyn M. Mulroney, Caitlin L. Costello, James K. Mangan, Edward D. Ball, Ah-Reum Jeong, Joseph Maroge, Michelle Padilla, Dimitrios Tzachanis

Blood (2023) 142 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2023-173906

Published: 2023

Journal Articles

A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care

Divya Koura, Dimitrios Tzachanis, Edward D. Ball, Caitlin Costello, Aaron M Goodman, James K. Mangan, Carolyn Mulroney, Joseph Maroge, Michelle Padilla, Peggy Breslin, Jodi Garrett, Kimberly McConnell

Blood (2021) 138 (Supplement 1): 1816.

https://doi.org/10.1182/blood-2021-145824

Published: 2021

Journal Articles

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

James K. Mangan, MD PhD, Imran Ajmal, MBBS, Noelle V. Frey, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, Martin Carroll, MD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 5155.

https://doi.org/10.1182/blood-2019-131668

Published: 2019

Journal Articles

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Shannon R. McCurdy, MD, Shannon H. Gier, BS, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Alexander E. Perl, MD, Ivan Maillard, MD PhD, Keith W. Pratz, MD, David L. Porter, MD, Martin P. Carroll, MD, Phyllis A. Gimotty, PhD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 2209.

https://doi.org/10.1182/blood-2019-124468

Published: 2019

Journal Articles

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Mitchell E. Hughes, PharmD, Tracy M. Krause, PharmD, Colleen Timlin, PharmD, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4023.

https://doi.org/10.1182/blood-2018-99-112604

Published: 2018

Journal Articles

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Gee Youn (Geeny) Kim, PharmD, Jonathan Burns, PharmD, Craig W. Freyer, PharmD, Keith Hamilton, MD, Mindy Schuster, MD MSCE, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, David L. Porter, MD, Selina Luger, MD, Alison W. Loren, MD MS

Blood (2018) 132 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2018-99-119168

Published: 2018

Journal Articles

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Colleen Timlin, PharmD, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, Selina Luger, MD, Jacqueline Smith, MSN, CRNP, Edward Stadtmauer, David L. Porter, MD

Blood (2018) 132 (Supplement 1): 5696.

https://doi.org/10.1182/blood-2018-99-111550

Published: 2018

Journal Articles

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Christine M. McMahon, MD, Nya Nelson, MD PhD, Alex Ganetsky, PharmD, James K. Mangan, MD PhD, Noelle V. Frey, MD, Alexander E. Perl, MD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alison W. Loren, MD MS, Elizabeth O. Hexner, MD MS, Adam Bagg, MD, Jennifer J.D. Morrissette, PhD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2018-99-116415

Published: 2018

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Benjamin M Manning, MD PhD, Robyn T Sussman, PhD, Safoora Deihimi, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, Selina Luger, MD, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Jennifer J.D. Morrissette, PhD, Alexander E. Perl, MD, Edward A. Stadtmauer, MD FACP, David L. Porter, MD, Saar I. Gill, MD PhD

Blood (2018) 132 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2018-99-117410

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Christopher C Walling, BS, Pamela A Shaw, PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth O. Hexner, MD, Alison W Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Mary Ellen Martin, MD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David L. Porter, MD

Blood (2016) 128 (22): 2309.

https://doi.org/10.1182/blood.V128.22.2309.2309

Published: 2016

Journal Articles

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Alex Ganetsky, PharmD, BCOP, Jennifer H Han, MD MSCE, Mitchell E Hughes, PharmD, Daria V. Babushok, MD PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth Hexner, MD, Alison Wakoff Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, Craig W. Freyer, PharmD, BCOP, Cheryl Gilmar, MT, David L Porter, MD

Blood (2016) 128 (22): 2225.

https://doi.org/10.1182/blood.V128.22.2225.2225

Published: 2016

Journal Articles

Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract

Alex Ganetsky, PharmD, BCOP, Noelle V Frey, MD, Alison W Loren, MD MS, Elizabeth O. Hexner, MD, James K Mangan, MD PhD, Saar I Gill, MBBS, PhD, Selina Luger, MD, Adam D. Cohen, MD, Daria V Babushok, MDPhD, Edward A Stadtmauer, MD, Jacqueline Smith, CRNP, William R. Drobyski, MD, Sarah K Kraus, PharmD, Colleen Timlin, PharmD, BCOP, David L. Porter, MD

Blood (2016) 128 (22): 2245.

https://doi.org/10.1182/blood.V128.22.2245.2245

Published: 2016

Journal Articles

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Jingmei Hsu, MD PhD, Anita J. Kumar, MDMS, Martin P. Carroll, MD, Noelle V. Frey, MDMS, Nirav N. Shah, MD, Zhao Jianhua, PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, James K. Mangan, MDPhD, Alexander E. Perl, MD, David Porter, MD, Jennifer Morrissette, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2343.

https://doi.org/10.1182/blood.V124.21.2343.2343

Published: 2014

Journal Articles

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Ran Reshef, MD, James K. Mangan, MDPhD, Selina M. Luger, MD, Alison Wakoff Loren, MDMS, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, Edward A. Stadtmauer, MD, Robin E. Blauser, BSN RN, Lee P. Richman, BA, Austin P. Huffman, BA, Alex Ganetsky, PharmD, Edward P. Acosta, PharmD, James A. Hoxie, MD, Rosemarie Mick, MS, Robert H. Vonderheide, MDDPhil, David L. Porter, MD

Blood (2014) 124 (21): 2491.

https://doi.org/10.1182/blood.V124.21.2491.2491

Published: 2014

Journal Articles

Acute Cholecystitis Occurs More Commonly Than Expected Following Allogeneic Hematopoietic Stem Cell Transplantation and Is Ineffectively Diagnosed Using Abdominal Ultrasound

Stephen J. Bagley, MD, Alison R. Sehgal, MD, Noelle V. Frey, MD, Saar Gill, MD, PhD, Elizabeth Hexner, MD, Alison W. Loren, MD, James K. Mangan, MD, PhD, David L. Porter, MD, Ran Reshef, MD, Edward A. Stadtmauer, MD, Selina Luger, MD

Blood (2013) 122 (21): 2046.

https://doi.org/10.1182/blood.V122.21.2046.2046

Published: 2013

Journal Articles

Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance.

Alexander E Perl, MD, Grace R Jeschke, Catherine C Smith, MD, James K. Mangan, MD, PhD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2012) 120 (21): 2453.

https://doi.org/10.1182/blood.V120.21.2453.2453

Published: 2012

Journal Articles

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

Blood (2012) 120 (21): 143.

https://doi.org/10.1182/blood.V120.21.143.143

Published: 2012

Journal Articles

A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia

Noelle V. Frey, MD, Elizabeth O. Hexner, MD, David L Porter, MD, James K. Mangan, MD, PhD, Alison W. Loren, MD, Joseph Hatem, MD, Adam Bagg, MD, Alexander E Perl, MD, Donald E Tsai, MD PhD, Courtney D. DiNardo, MD, Daniel Heitjian, PhD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2012) 120 (21): 3576.

https://doi.org/10.1182/blood.V120.21.3576.3576

Published: 2012

Journal Articles

Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,

Alexander E Perl, MD, Grace R Jeschke, Catherine C. Smith, MD, James K. Mangan, MD, PhD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2011) 118 (21): 3502.

https://doi.org/10.1182/blood.V118.21.3502.3502

Published: 2011

NARROW

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

A Prospective Randomized Clinical Trial Comparing a Calcineurin-Free Gvhd Prophylaxis Regimen with Post-Transplant Cyclophosphamide and Abatacept to Methotrexate and Tacrolimus

A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Risk of Invasive Fungal Infections in Patients with High-Risk MDS and AML Receiving Hypomethylating Agents

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Acute Cholecystitis Occurs More Commonly Than Expected Following Allogeneic Hematopoietic Stem Cell Transplantation and Is Ineffectively Diagnosed Using Abdominal Ultrasound

Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance.

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia

Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only